- Company
- Family testing for rare genetic diseases are needed
- by Eo, Yun-Ho Jun 9, 2021 06:08am
- As the number of rare genetic diseases that can be managed increases, the importance of early diagnosis through family tests is emerging. According to the KDCA's "2019 Statistical Yearbook of Rare Disease Patients," the number of new rare diseases in 2019 stood at 55,499 with about one per 1,000 population. The number of patients suffering
- Company
- Merz’s OTC drug Pantogar released as health functional food
- by Nho, Byung Chul Jun 9, 2021 06:08am
- The hair loss OTC drug Pantoga received attention after its unexpected release as a health functional food recently, after removing some of its ingredients. Pantogar was approved by the Korean Ministry of Food and Drug Safety in 2002, and the original developer, Merz in Germany, had globally launched Pantogar in 1976. The newly launche
- Company
- MNCs bid for ‘themed’ victory with innovation and legacy
- by Eo, Yun-Ho Jun 9, 2021 06:07am
- Whichever the cause, the decision of the Big Pharmas to ‘focus on their strengths’ is more than just a pretext for reorganizing their businesses. Setting a clear ‘theme’ can have a positive effect on the image of a company. Also, dividing its business does not mean a loss of drive. However, such divisions will bring one company to los
- Company
- Patent dispute over Pelubi SR is not over
- by Kim, Jin-Gu Jun 9, 2021 06:07am
- The patent dispute of Daewon's anti-inflammatory drug Pelubi SR continues. Youngjin, Huons, and Chong Kun Dang won patent dispute of Pelubi. Among them, Youngjin has received generic for exclusivity alone. According to the pharmaceutical industry on the 7th, at least three companies are considering patent challenges for Pelubi SR: Mothers
- Policy
- 200 million tablets of Acetaminophen are available
- by Kim, Jung-Ju Jun 9, 2021 06:07am
- The government has stressed that Acetaminophen is well stocked before more people are vaccinated. Pre-dosing before inoculation does not fit medical information and does not require purchasing only certain brands (ex:Tylenol). COVID-19 Central Disaster and Safety Counters Headquaters (CDSCHQ) told in a regular briefing this afternoon that
- Product
- Ask for Acetaminophen, instead of Tylenol
- by Kang, Shin-Kook Jun 8, 2021 09:12pm
- "If fever or muscle pain occurs after vaccination, ask for Acetaminophen to the pharmacy." As the Tylenol shortage continues, the movement to change public perception begins. Rep. Seo Young-seok of the Democratic Party of Korea visited the Korean Pharmaceutical Association Hall on the morning of the 4th and announced that he would start an SN
- Company
- Hemlibra reimbursement disapproval raises anxiety
- by Nho, Byung Chul Jun 8, 2021 06:01am
- The head-on clash between the ‘standard to first consider immune tolerance induction (ITI·antibody removal) therapies’ and the ‘due prescription rights of doctors·convenience in administration·saving NHI finances’ have received industry attention. On the 3rd, the Health Insurance Review and Assessment Service (HIRA) held a Pediatri
- Policy
- PVA is a variable in the negotiation of α-GPC recovery
- by Lee, Hye-Kyung Jun 8, 2021 06:01am
- Re-negotiation on benefit recovery and PVA negotiation related to pharmaceuticals with the brain functional improvement agent "Choline alfoscerate" have emerged as variables. On the 3rd, the MOHW ordered the NHIS to conduct negotiations on 123 items of Choline alfoscerate for 40 days from June 4 to July 13. Choline alfoscerate recovery
- Company
- Pros and cons of the spin-offs and sales of Big Pharmas
- by Eo, Yun-Ho Jun 8, 2021 06:01am
- Mergers, spin-offs, buying, selling... news shows that global Big Pharmas have been busy constantly changing their shape. In particular, the issue that gained the most attention for the past few years was the companies' spin-offs and sales. Although the companies' made the decision under the premise of ‘focusing on one’s strengths,’ s
- Policy
- Pipeltro/Delstrigo will be reimbursed if the amount offered
- by Lee, Hye-Kyung Jun 8, 2021 06:00am
- Pipeltro (Doravirine) and Delstrigo (Doravirine, Lamivudine, Tenofovir), the HIV treatment by MSD, are the two major human immunodeficiency virus. And, were declared "Conditional Coverage" at the first step of the reimbursement if it was accepted below the appraised amount. On the 3rd, the HIRA held the 5th Pharmaceutical Benefits Advisory Co
